**Supplemental Table 1**

**IgG index following SARS-CoV-2 vaccination or COVID-19 for additional DMTS**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| IgG AU/mLMean ± SE [range]% IgG positive | Post COVID-19 no vaccine | Time-point 1:≤3m Post 2nd vaccine | Time-point 2:~6m Post 2nd vaccine | Time-point 3:≤3m Post 3rd vaccine |
| MS patients |
| Anti CD-20 mAb(Rituximab)  |  | N=243 ± 39[4 – 82]50% |  |  |
| Azathioprine |  | N=1527 100% | N=21480 ± 852[628– 2332]100% |  |
| Diroximel Fumarate |  |  | N=1308 100% |  |
| Interferon β (Avonex) | N=122699(100%) | N=89376 ± 4517[1735 – 40000]100% | N=92477 ± 1589[80 – 14783]100% | N=519450 ± 7163[2014 – 37181]100% |
| Interferon β (Betaferon) |  | N=21457 ± 683[775 – 2140]100% | N=1733100% | N=39940 ± 4343[1649 – 16330]100% |
| Interferon β (Plegridy) |  |  | N=1157 100% |  |
| Interferon β (Rebif) |  | N=97876 ± 2312[248 – 23250]100% | N=4389 ± 161[35 – 705]75% | N=5 17510 ± 6117[3995 – 40000]100% |
| S1PR modulator (Ponesimod) |  | N=2174 ± 12[162 – 186]100% |  | N=157100% |

AU- arbitrary units, IgG – immunoglobulin G, m- months, mAb – monoclonal antibody, SE- standard error, S1PR-Sphingosine 1-phosphate receptor.